Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Qisi Lu"'
Autor:
Xueting Xia, Zongxin Yang, Qisi Lu, Zhenyun Liu, Lei Wang, Jinwen Du, Yuhua Li, Dong-Hua Yang, Shaojie Wu
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-21 (2024)
Abstract In many hematologic malignancies, the adoptive transfer of chimeric antigen receptor (CAR) T cells has demonstrated notable success; nevertheless, further improvements are necessary to optimize treatment efficacy. Current CAR-T therapies are
Externí odkaz:
https://doaj.org/article/916e13eb19b847b59e6232e3794078a8
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Externí odkaz:
https://doaj.org/article/c0b5cafc089042adb34a5f7c3e424259
Autor:
Congying, Gao, Xiangyu, Ma, Zifan, Zhang, Qisi, Lu, Charles R, Ashby, Liuya, Wei, Zhe-Sheng, Chen
Publikováno v:
Drugs of today (Barcelona, Spain : 1998). 58(6)
Acute lymphoblastic leukemia (ALL) is a neoplastic disease characterized by the malignant proliferation of lymphoid cells in the blood and bone marrow. It accounts for approximately 75% of childhood leukemia. Lymphoblastic lymphoma (LBL) is a type of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::724d30010d30e83fa13d0b07af37ca15
https://pubmed.ncbi.nlm.nih.gov/35670704
https://pubmed.ncbi.nlm.nih.gov/35670704
Publikováno v:
Cancer Research. 83:2843-2843
Overcoming ATP-binding cassette subfamily G member 2 (ABCG2)-mediated multidrug resistance (MDR) has attracted the attention of scientists because one of the critical factors leading to MDR is the overexpression of ABCG2. Identification of novel chem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e3a500f08b39659e28b83fc6139912d
https://doi.org/10.1158/1538-7445.am2023-2843
https://doi.org/10.1158/1538-7445.am2023-2843
Autor:
Xuan Zhou, Ziyuan Lu, Guanlun Gao, Bolin He, Qisi Lu, Lin Li, Xiaoli Liu, Jixian Huang, Na Xu, Chengyun Pan, Yuling Li
Publikováno v:
Oncology Letters
Tyrosine kinase inhibitors (TKIs), including imatinib, dasatinib and nilotinib, are effective forms of therapy for various types of solid cancers and Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia. A number of TKIs have been known to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e651eff59a2ce2325d54590b430565e7
https://doi.org/10.3892/ol.2017.6294
https://doi.org/10.3892/ol.2017.6294
Publikováno v:
Drugs of Today. 57:571
Diffuse large B-cell lymphoma (DLBCL) is a common lymphoproliferative and invasive disease. The current first-line regimen for the treatment of DLBCL is R-CHOP, which is the combination of rituximab, cyclophosphamide, doxorubicin, vincristine and pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ace7b7f26b3c9a5940c0fd2ddff65dd4
https://doi.org/10.1358/dot.2021.57.9.3306767
https://doi.org/10.1358/dot.2021.57.9.3306767
Autor:
Xuan Zhou, Rui Cao, Yuling Li, Jixian Huang, Lin Li, Xiaoli Liu, Ziyuan Lu, Jing Sun, Qifa Liu, Qingfeng Du, Huan Li, Qisi Lu, Na Xu
Publikováno v:
Journal of Cancer
Deletion of cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) is well known in many hematologic malignancies, but only few reports have investigated this deletion effect on clinical prognosis. This study performed analysis of the CDKN2 deletion in 21
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b6d882e69c8271c18e2e9572f8f79a5
http://europepmc.org/articles/PMC4615347
http://europepmc.org/articles/PMC4615347
Autor:
Guanlun Gao, Xiaoli Liu, Qingfeng Du, Li Ding, Yajuan Xiao, Yuling Li, Na Xu, Xuan Zhou, Ling Li, Rong Li, Qisi Lu
Publikováno v:
Leukemia & Lymphoma. 56:2162-2169
The objective of this study was to determine the changes in protein profiles of K562 chronic myeloid leukemia (CML) cells in response to Homoharringtonine (HHT). HHT treatment significantly increased apoptosis of K562 cells. Proteomic analyses indica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48065882885ecd1f7e24db8035dbc773
https://doi.org/10.3109/10428194.2014.976818
https://doi.org/10.3109/10428194.2014.976818
Publikováno v:
Annals of Hematology. 94:865-867
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2871e44d5d88358b558d2fcd0ae685f8
https://doi.org/10.1007/s00277-014-2248-0
https://doi.org/10.1007/s00277-014-2248-0
Autor:
Lin Li, Rui Cao, Yuling Li, Qisi Lu, Xuan Zhou, Ziyuan Lu, Libin Liao, Jixian Huang, Na Xu, Xiaoli Liu
Publikováno v:
Clinical lymphoma, myelomaleukemia. 15(12)
Background The monosomal karyotype (MK) is a well-known adverse prognostic factor and has been found to be related to poor outcome in patients with acute myeloid leukemia (AML). However, the outcome in MK-positive AML patients undergoing different th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c465541143d2cdeac3cf7d7b12918fdb
https://pubmed.ncbi.nlm.nih.gov/26482108
https://pubmed.ncbi.nlm.nih.gov/26482108